Dupixent trial meets endpoints for childhood eczema
The Phase III trial for Sanofi/Regeneron's Dupixent (dupilumab) plus topical corticosteroids (TCS) for the treatment of moderate-to-severe atopic dermatitis (eczema)...
Continue Reading →
